It is also worth noticing that ivabradine, the unique clinically approved non-selective HCN blocker used for coronary heart disease and heart failure (DiFrancesco and Camm, 2004; DiFrancesco and Borer, 2007) has been reported to reduce mechanical allodynia, inflammatory and neuropathic pain in animal models, further supporting the involvement of HCN channels in pain transmission (Noh et al., 2014; Young et al., 2014). The gene discussed is MALAT1; the disease is coronary artery disorder.